The Department of Justice Reports Worldwide Resolution of Civil and Criminal Resolution Investigations with Purdue Pharma, an Opioid Manufacturer.

The Department of Justice Reports Worldwide Resolution of Civil and Criminal Resolution Investigations with Purdue Pharma, an Opioid Manufacturer.

Purdue Pharma LP Admits Guilt to Kickback Conspiracy Focused at Increasing Opioids Prescriptions

On 21st October 2020, the Justice Department reported a world-wide resolution of its civil and criminal investigations into the Opioid manufacturer Purdue Pharma LP. The resolutions with Purdue Pharma LP are subject to the bankruptcy court’s approval.

Jeffrey A. Rosen, Deputy Attorney General, stated that the diversion and abuse of opioids prescriptions had given rise to a national tragedy of deaths and addiction, in addition to those contributed by illegal street opioids. Rosen further added that with criminal sentencing, federal settlement of over 8,000,000,000 USD, and the dissolution of a firm and repurposing its assets completely for the public benefit. The resolution in the 21st October 2020 press release re-affirms that the Justice Department will not back down in its multi-pronged efforts and work to fight the opioids crisis.

U.S. Attorney Christina E. Nolan for the District of Vermont stated that Purdue Pharma’s extensive criminal activities included reimbursing kickback in exchange for designing medical software to influence innocent medical physicians. Purdue Pharma’s drug promoters paid to violate the sanctity of the patient-physician relationship so that it could sway medical decisions and increase prescriptions of its most potent opioids. Purdue Pharma entity is at the moment ready to admit guilt for a second time to a scheme involving illegal marketing of highly addictive opioids prescriptions. The resolution will warn and serve as a reminder that the firm values profit more than people during the height of the opioid crisis.

U.S. Attorney Rachael A. Honig for the District of New Jersey stated that Purdue Pharma put profits over patients for years by promoting and selling its dangerous opioid pills to healthcare practitioners that it had a good reason to think they were diverting those opioids prescriptions to abusers. Honig further added that Purdue Pharma tricked the Drug Enforcement Administration concerning its measures to stop and prevent such diversion, and it utilized that deception to obtain higher limits on the number of its products it was legally authorized to sell. Purdue Pharma further reimbursed kickbacks to providers to motivate them to prescribe even more Purdue Pharma’s opioid products. Purdue Pharma is currently in bankruptcy, but it still must be held accountable for these criminal actions. Honig concluded by affirming that the resolutions announced on 21st October 2020 does just that.

Purdue Pharma has accepted to admit guilt in a federal court in New Jersey to three-felony count information charging it with one charge of dual-object scheme to swindle the United States and to breach the Food, Drug, and Cosmetic Statute, and two conspiracy counts of breaching the Federal Anti-Kickback Act. The criminal resolution comprises the largest penalties ever imposed against a Pharmaceutical manufacturer, including a 3,544,000,000 USD criminal fine and an additional 2,000,000,000 USD in criminal forfeiture. For the 2,000,000,000 USD forfeiture, the firm will reimburse 225,000,000 USD on the effective bankruptcy date, and the Department is ready to credit the value conferred by the firm to Local and State governments under the Department’s anti-pilling on and coordination policy. Purdue Pharma has further assented to a civil settlement agreement of 2,800,000,000 USD to settle its civil liability under the False Claims Statute.

Regarding the District of Vermont investigations, Purdue Pharma will confess to scheming to breach the Federal Anti-Kickback Statute. This is the first prosecution in the history of the United States charging a pharmaceutical firm for plotting with an EHR (electronic health records) firm to influence medical physician’s prescribing.

From nearly April 2016 through December 2016, Purdue Pharma made reimbursement to Practice Fusion, Inc., an EHR firm, in exchange for recommending, referring, and arranging for the purchasing of Purdue Pharma’s extended-release opioid pills, such as OxyContin, Hysingla, and Butrans. Purdue Pharma and Practice Fusion schemed to design CDS (clinical decision support) alert inserted in medical software to increase ERO (extended-release opioid) prescriptions. Purdue Pharma’s drug promoters financed the alerts that were submitted to medical physicians as impartial clinic alerts when, in the real sense, they were just part of a clandestine illegal marketing conspiracy. Purdue Pharma’s internal marketing documents outlined the leading performance indicators of the program as; ‘Increase in ERO prescribing.’

Purdue Pharma, as part of the resolution, will be needed to host and create a permanent and public document repository containing documents associated with the charges and purported civil violations. The resolutions do not contain the criminal release of any person, including the Sackler family members, nor any of the firm’s employees or executives getting civil releases. The 21st October 2020 resolution does not settle claims that the States may have against Purdue Pharma nor does it hinder the Debtors’ ability to recover fraudulent transfers.

United States Assistant Attorneys Owen C.J. Foster and Michael P. Drescher handled the District of Vermont’s investigation. The Federal Bureau of Investigation’s field office in New York and Washington, DC, and the U.S. Health and Human Services Department- Office of Inspector General helped and supported the investigation. Vermont Health Care Fraud Investigators Richard Lewis and George Thabault offered critical and significant investigative resources to the Vermont-based team. The Vermont District collaborated with its colleagues and partners in the District of New Jersey, such as the United States Assistant Attorneys Sean M. Sherman, J. Stephen Ferketic, Melissa Wangenheim, Nicholas P. Grippo, Marihug P. Cedeno, and Nicole F. Mastropieri; Consumer Protection Branch Trial Attorneys Kara M. Traster, Gabriel H. Scannapieco, Rachel E. Baron, Maryann N. McGuire, Hilary Perkins, and Michael L. Collyer; and Civil Frauds Trial Attorneys Albert P. Mayer, Kristen M. Murphy, Claire L. Norsetter, Christelle Klovers, Kelley Hauser, and Alicia Bentley.  The Purdue Pharma bankruptcy matter is being handled by the Civil Division’s Commercial Litigation Branch, Corporate/Finance Section, and the U.S. Attorney’s Office for the Southern District of New York. Purdue Pharma is represented by Attorneys Patrick Fitzgerald of the law firm Skadden, Slate, Arps, Meagher & Flom LLP, and Jeffrey Bucholtz of the law firm King & Spalding.

The charges settled by the civil settlements are merely accusations, and there is no liability determination in civil matters, except to the extent of Purdue Pharma’s confessions as part of the criminal resolution.

Individuals who contribute or conspire to commit Health Care Fraud, Money Laundering, or Breach the Controlled Substance Statutes violate the law. Committing Money Laundering, breaking the Controlled Substance Statute, or contributing to Health Care Fraud conspiracies is a severe crime. Any medical doctor or any person who violates the Controlled Substance Statute, contributes to a Health Care Fraud conspiracy or commits Money Laundering is severely punished or penalized if found guilty of the criminal undertakings. If indicted for Money Laundering, breaching Controlled Substance Statute, or Health Fraud Conspiracy, you must seek legal help or representation to pursue and protect your rights. Receiving the best legal representation or advice leads to the positive results of your case. Hire the Healthcare Fraud Group now if you want the best legal representation or advice to attain positive results in your case. Our highly trained team of skilled criminal attorneys contains superlative defense lawyers with excellent experience and matchless case win history. They are highly conversant and understand the need to prove innocence after the indictment of any offense, including any of the crimes mentioned above. Call us now or anytime at 888-402-4054 for any legal help, advice, or representation you may need.

Schedule a Confidential Initial Compliance Assessment with Our Federal Health Care Group